



**HAL**  
open science

## Mast cells in spondyloarthritis, more than simple inflammatory bystanders?

Laura Polivka, Laurent Frenzel, Jean-Yves Jouzeau, Olivier Hermine, David Moulin

► **To cite this version:**

Laura Polivka, Laurent Frenzel, Jean-Yves Jouzeau, Olivier Hermine, David Moulin. Mast cells in spondyloarthritis, more than simple inflammatory bystanders?. *Therapeutic advances in musculoskeletal disease*, 2020, 12, pp.1759720X2097190. 10.1177/1759720X20971907 . hal-03090864

**HAL Id: hal-03090864**

**<https://hal.science/hal-03090864v1>**

Submitted on 5 Sep 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Mast cells in spondyloarthritis, more than simple inflammatory bystanders?

Laura Polivka, Laurent Frenzel, Jean-Yves Jouzeau, Olivier Hermine\* and David Moulin\* 

*Ther Adv Musculoskel Dis*

2020, Vol. 12: 1–2

DOI: 10.1177/  
1759720X20971907

© The Author(s), 2020.  
Article reuse guidelines:  
sagepub.com/journals-  
permissions

Quantitative and qualitative evidences indicate that mast cells (MCs) are important players in spondyloarthritis (SpA) pathogenesis. First, the number of MCs found in the synovial tissue of patients with SpA is higher than the number found in rheumatoid arthritis (RA), which is itself 6–25 times higher than the number in patients with osteoarthritis.<sup>1</sup> Secondly, MCs found in the synovium of patients with peripheral SpA or in the facet joint of axial SpA are high producers/stockers of IL-17.<sup>2,3</sup> IL-17 is a key cytokine mediating inflammation in SpA as demonstrated by the efficacy of anti-IL17 biotherapies in psoriatic or non-psoriatic peripheral SpA and axial SpA.<sup>4,5</sup>

Clinically, patients suffering from mastocytosis, a heterogeneous group of neoplastic conditions characterized by the expansion and accumulation of MCs in one or more organs, have a higher prevalence of SpA than in the general population. Mastocytosis and spondyloarthritis share a same cortège of symptoms and comorbidities (e.g. gastrointestinal manifestations, joint pain and tendinitis, osteoporosis), from which association with MC overactivation or dysfunction is highly suspected or characterized.<sup>6</sup>

The final proof of MCs involvement in SpA has suffered from the paucity of reliable inducible SpA animal models. Experiments using MC-deficient mice have been performed exclusively on collagen-induced arthritis or K/BxN serum-induced arthritis, two relevant models to study the pathogenesis of RA but not of SpA.

In that respect, the recent study of Regan-Komito *et al.* is of interest since, using arthritis-prone SKG mice in which a single intraperitoneal (IP) injection of a microbial polysaccharide,<sup>7</sup> triggers a SpA-like phenotype, they demonstrate that extramedullary haematopoiesis (EMH) occurs in

joints.<sup>8</sup> This EMH was oriented towards myelopoiesis and likely to be granulocyte-macrophage colony-stimulating factor (GM-CSF) driven. Regan-Komito *et al.* found that, besides innate lymphoid cells, MCs contributed greatly to GM-CSF production in this model. Further confirming the importance of MCs in this model, MC blockade by cromolyn dampens SpA severity.

Whether EMH occurs in human SpA is uncertain, but recent studies suggest GM-CSF involvement in the pathophysiology of SpA, since transcriptomic and cytometry studies have revealed GM-CSF expression in lymphocytes from these patients.<sup>9,10</sup>

Tyrosine kinase inhibitors (TKI) like Masitinib, Imatinib or Midostaurin have demonstrated clinical activity in systemic mastocytosis, by blocking MC activation/proliferation.<sup>11,12</sup> Thus, it is tempting to suggest that TKI with high safety profiles may be used in SpA to block joint inflammation as it has been reported in RA.<sup>13,14</sup>

Overall, although fundamental studies are required to clarify the role of MCs in SpA, we can conclude that these innate immune cells are not simple inflammatory bystanders but rather drivers of pain and inflammation.

## Key message

Recent findings support an active role for mast cells in SpA, opening new therapeutic insights.

## Conflict of interest statement

Masitinib is under clinical development by AB Science. OH is the President of the Scientific Committee of AB Science. All remaining authors have no competing interests.

Correspondence to:  
**David Moulin**  
IMoPA, UMR7365 CNRS-  
Université de Lorraine;  
CHRU de Nancy, Contrat  
d'interface, Vandœuvre-  
lès-Nancy, France  
[david.moulin@univ-lorraine.fr](mailto:david.moulin@univ-lorraine.fr)

**Laura Polivka**  
Department of  
Dermatology, Reference  
Center for Genodermatoses  
(MAGEC), Necker-Enfants  
Malades Hospital (AP-HP5),  
Paris-Centre University;  
Imagine Institute, INSERM  
U1163, Laboratory of  
Molecular Mechanisms of  
Hematologic Disorders and  
Therapeutic Implications,  
Paris, France; French  
National Reference  
Center for Mastocytosis  
(CEREMAST)

**Laurent Frenzel**  
**Olivier Hermine**  
Department of  
Hematology, Necker-  
Enfants Malades Hospital  
(AP-HP5), Paris-Centre  
University; Imagine  
Institute, INSERM  
U1163, Laboratory of  
Molecular Mechanisms of  
Hematologic Disorders  
and Therapeutic  
Implications, Paris,  
France; French National  
Reference Center for  
Mastocytosis (CEREMAST)

**Jean-Yves Jouzeau**  
IMoPA, UMR7365 CNRS-  
Université de Lorraine,  
Vandœuvre-lès Nancy,  
France

\*These authors  
contributed equally

### Contributorship

All authors drafted and revised the manuscript. All authors approved the final version of the manuscript.

### Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the French PIA project « Lorraine Université d'Excellence », reference ANR-15-IDEX-04-LUE » (JYJ) and the Fondation Arthritis (DM).

### ORCID iD

David Moulin  <https://orcid.org/0000-0001-6619-5769>

### References

1. Noordenbos T, Yeremenko N, Gofita I, *et al.* Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. *Arthritis Rheum* 2012; 64: 99–109.
2. Chen S, Noordenbos T, Blijdorp I, *et al.* Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content. *Rheumatology (Oxford)* 2019; 58: 617–627.
3. Appel H, Maier R, Wu P, *et al.* Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. *Arthritis Res Ther* 2011; 13: R95.
4. Molto A and Sieper J. Peripheral spondyloarthritis: Concept, diagnosis and treatment. *Best Pract Res Clin Rheumatol* 2018; 32: 357–368.
5. Jones A, Ciurtin C, Ismajli M, *et al.* Biologics for treating axial spondyloarthritis. *Expert Opinion on Biological Therapy* 2018; 18: 641–652.
6. Bader-Meunier B, Bulai Livideanu C, Larroche C, *et al.* Association of mastocytosis with inflammatory joint diseases: a series of 31 patients. *Semin Arthritis Rheum* 2014; 44: 362–365.
7. Ruutu M, Thomas G, Steck R, *et al.*  $\beta$ -glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. *Arthritis Rheum* 2012; 64: 2211–2222.
8. Regan-Komito D, Swann JW, Demetriou P, *et al.* GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. *Nat Commun* 2020; 11: 155.
9. Al-Mossawi MH, Chen L, Fang H, *et al.* Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. *Nat Commun* 2017; 8: 1510.
10. Blijdorp ICJ, Menegatti S, van Mens LJJ, *et al.* Expansion of interleukin-22- and granulocyte-macrophage colony-stimulating factor-expressing, but not interleukin-17a-expressing, group 3 innate lymphoid cells in the inflamed joints of patients with spondyloarthritis. *Arthritis Rheumatol* 2019; 71: 392–402.
11. Lortholary O, Chandesaris M-O, Bulai Livideanu C, *et al.* Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. *Lancet* 2017; 389: 612–620.
12. Piris-Villaespesa M and Alvarez-Twose I. Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. *Front Pharmacol* 2020; 11: 443.
13. Walker UA. More about masitinib. *Arthritis Res Ther* 2009; 11: 120.
14. Tebib J, Mariette X, Bourgeois P, *et al.* Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. *Arthritis Res Ther* 2009; 11: R95.